Adams Respiratory Therapeutics (Nasdaq: ARXT) reports Q1 of $0.61 per share, ex-items, 15 cents better than estimates. Revenues came ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE